JPWO2022056484A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022056484A5 JPWO2022056484A5 JP2023516809A JP2023516809A JPWO2022056484A5 JP WO2022056484 A5 JPWO2022056484 A5 JP WO2022056484A5 JP 2023516809 A JP2023516809 A JP 2023516809A JP 2023516809 A JP2023516809 A JP 2023516809A JP WO2022056484 A5 JPWO2022056484 A5 JP WO2022056484A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- subject
- composition
- disorder
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 115
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 42
- 206010002022 amyloidosis Diseases 0.000 claims description 31
- 230000003442 weekly effect Effects 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 21
- 208000034578 Multiple myelomas Diseases 0.000 claims description 20
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 238000012423 maintenance Methods 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 238000011374 additional therapy Methods 0.000 claims description 12
- 238000001990 intravenous administration Methods 0.000 claims description 12
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 201000001268 lymphoproliferative syndrome Diseases 0.000 claims description 10
- 238000011476 stem cell transplantation Methods 0.000 claims description 9
- 102000003964 Histone deacetylase Human genes 0.000 claims description 8
- 108090000353 Histone deacetylase Proteins 0.000 claims description 8
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 8
- 238000002512 chemotherapy Methods 0.000 claims description 8
- -1 daratumumab Chemical compound 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims description 8
- 229940068968 polysorbate 80 Drugs 0.000 claims description 8
- 235000017281 sodium acetate Nutrition 0.000 claims description 8
- 239000001632 sodium acetate Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 208000002774 Paraproteinemias Diseases 0.000 claims description 7
- 208000010626 plasma cell neoplasm Diseases 0.000 claims description 7
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 208000037259 Amyloid Plaque Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 208000014951 hematologic disease Diseases 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 6
- 238000010255 intramuscular injection Methods 0.000 claims description 6
- 239000007927 intramuscular injection Substances 0.000 claims description 6
- 239000002736 nonionic surfactant Substances 0.000 claims description 6
- 238000010254 subcutaneous injection Methods 0.000 claims description 6
- 239000007929 subcutaneous injection Substances 0.000 claims description 6
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 claims description 5
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 229960001467 bortezomib Drugs 0.000 claims description 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims description 4
- 239000006172 buffering agent Substances 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 229960001334 corticosteroids Drugs 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960002204 daratumumab Drugs 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 238000001962 electrophoresis Methods 0.000 claims description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 208000024963 hair loss Diseases 0.000 claims description 4
- 230000003676 hair loss Effects 0.000 claims description 4
- 210000002216 heart Anatomy 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 229950007752 isatuximab Drugs 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 4
- 229960004942 lenalidomide Drugs 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 229960001924 melphalan Drugs 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- 230000007935 neutral effect Effects 0.000 claims description 4
- 230000030147 nuclear export Effects 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 239000003207 proteasome inhibitor Substances 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000001356 surgical procedure Methods 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims description 4
- 229960001183 venetoclax Drugs 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 208000023761 AL amyloidosis Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 102000004506 Blood Proteins Human genes 0.000 claims description 2
- 108010017384 Blood Proteins Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000021161 Plasma cell disease Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims description 2
- 210000002346 musculoskeletal system Anatomy 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims 1
- 102000001049 Amyloid Human genes 0.000 description 2
- 108010094108 Amyloid Proteins 0.000 description 2
- 101710163305 Fibril protein Proteins 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078258P | 2020-09-14 | 2020-09-14 | |
| US63/078,258 | 2020-09-14 | ||
| US202063116100P | 2020-11-19 | 2020-11-19 | |
| US63/116,100 | 2020-11-19 | ||
| US202163176015P | 2021-04-16 | 2021-04-16 | |
| US63/176,015 | 2021-04-16 | ||
| PCT/US2021/050316 WO2022056484A1 (en) | 2020-09-14 | 2021-09-14 | Method of treating amyloidosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541191A JP2023541191A (ja) | 2023-09-28 |
| JPWO2022056484A5 true JPWO2022056484A5 (https=) | 2024-09-26 |
| JP2023541191A5 JP2023541191A5 (https=) | 2024-09-26 |
Family
ID=80631942
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516809A Pending JP2023541191A (ja) | 2020-09-14 | 2021-09-14 | アミロイドーシスを治療する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230364228A1 (https=) |
| EP (1) | EP4210753A4 (https=) |
| JP (1) | JP2023541191A (https=) |
| KR (1) | KR20230069161A (https=) |
| AU (1) | AU2021339851A1 (https=) |
| CA (1) | CA3192069A1 (https=) |
| IL (1) | IL301047A (https=) |
| MX (1) | MX2023002997A (https=) |
| WO (1) | WO2022056484A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022346750A1 (en) * | 2021-09-14 | 2024-04-11 | Caelum Biosciences, Inc. | Method of treating multiple myeloma |
| CN120322242A (zh) * | 2022-09-16 | 2025-07-15 | 联邦高等教育系统天普大学 | Bag3用于治疗心脏淀粉样变性的方法和用途 |
| WO2025194030A1 (en) | 2024-03-15 | 2025-09-18 | Alexion Pharmaceuticals, Inc. | Treatment of mayo stage iiib light chain amyloidosis |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5553963B2 (ja) * | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
| US20090028847A1 (en) * | 2007-04-12 | 2009-01-29 | Trustees Of Boston University | Multiple myeloma and al amyloid immunotherapy targeting immunoglobulin light chains and uses thereof |
| WO2016189491A1 (en) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Novel formulation |
| US11382974B2 (en) * | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
| PH12021552135A1 (en) * | 2019-03-05 | 2022-08-31 | Prothena Biosciences Ltd | Methods of treating al amyloidosis |
-
2021
- 2021-09-14 AU AU2021339851A patent/AU2021339851A1/en active Pending
- 2021-09-14 CA CA3192069A patent/CA3192069A1/en active Pending
- 2021-09-14 JP JP2023516809A patent/JP2023541191A/ja active Pending
- 2021-09-14 WO PCT/US2021/050316 patent/WO2022056484A1/en not_active Ceased
- 2021-09-14 MX MX2023002997A patent/MX2023002997A/es unknown
- 2021-09-14 US US18/026,185 patent/US20230364228A1/en active Pending
- 2021-09-14 KR KR1020237012401A patent/KR20230069161A/ko active Pending
- 2021-09-14 IL IL301047A patent/IL301047A/en unknown
- 2021-09-14 EP EP21867833.2A patent/EP4210753A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2641601T3 (en) | Methods for treating multiple myeloma using the combination therapy based on HuLuc63 with bortezomib | |
| US8501705B2 (en) | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions | |
| RU2005127429A (ru) | Активная иммунизация для создания антител к растворимому а-бета | |
| ES2984113T3 (es) | Composiciones y procedimientos para tratar la acumulación de tejidos grasos | |
| WO2002076503A1 (en) | Treatment of central nervous system diseases by antibodies against glatiramer acetate | |
| JP2024127990A (ja) | アミロイドーシスを処置するための組成物 | |
| EP3661553A2 (en) | Methods and compositions for treatment of amyloid deposition diseases | |
| JP2022539785A (ja) | ＴＡＣＩ－Ｆｃ融合タンパク質及びその用途 | |
| WO2020178638A1 (en) | Methods of treating al amyloidosis | |
| WO2013140787A1 (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| CN113087768B (zh) | 一种针对ETAR-RhoE通路的免疫原性短肽及其疫苗和改善心脏重塑的应用 | |
| KR20230031015A (ko) | 자가면역질환의 예방 또는 치료를 위한 항체의약품 | |
| EP3261672B1 (en) | Molecules disrupting pyruvate kinase m2 and integrin interaction and uses thereof | |
| JPWO2022056484A5 (https=) | ||
| CN113924099A (zh) | 针对免疫球蛋白轻链的单克隆抗体与抗体产生细胞和其他免疫细胞上的cd38细胞膜分子的组合治疗al淀粉样变性 | |
| WO2023174408A1 (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| JP7217287B2 (ja) | アミロイド症の処置および予防 | |
| JPWO2023043658A5 (https=) | ||
| WO2025067383A1 (zh) | 用TACI-Fc融合蛋白治疗抗体介导性排斥反应的方法 | |
| CN114980901A (zh) | 使用针对浆细胞的抑制剂或细胞毒性剂治疗慢性疲劳综合征的方法 | |
| EA044759B1 (ru) | Лечение и профилактика амилоидоза | |
| CN117815387A (zh) | Cdk4/6抑制剂和抗pd-l1抗体的联用药物组合物 | |
| CN121851157A (zh) | 卵黄IgY多克隆抗体及其组合物和应用 | |
| Reuter et al. | 7.1 Therapeutic Indication | |
| JPWO2023003815A5 (https=) |